Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis.
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy Read More »
